Commentary|Videos|September 9, 2025
How Sponsors Can Modernize Tools to Support Physicians
Author(s)Andy Studna, Senior Editor
In this video interview, Adrianne Rivard, senior community development manager at myTomorrows, explains why unified, real-time trial platforms are essential for reducing physician burden and improving patient access to studies.
Advertisement
In a recent video interview with Applied Clinical Trials, Adrianne Rivard, senior community development manager, myTomorrows, discussed the challenges physicians face in identifying clinical trials. Highlighting insights from a recent myTomorrows report on the need to streamline clinical operations, Rivard touched on the use of artificial intelligence (AI) to streamline pre-screening, which can reduce the need for multiple databases. She also discussed how AI tools are gaining use, necessitating compliance with data privacy standards and ongoing education to build trust among physicians.
ACT: Given that 61% of physicians cite fragmented systems and outdated registries as major barriers, where do you see the greatest opportunity for trial sponsors or CROs to simplify and modernize physician-facing tools?
Rivard: I think this is a great question, because we hear this a lot from physicians, and I think while it's great that there are databases and registries out there, more often than not, they're outdated or incomplete, and I think having a comprehensive, accurate, up to date system for these physicians, where they can identify what's really out there for their patients is critical. If you think about it, that can also be life changing in a way, if something's incorrect, whether something's recruiting or maybe it's not, and I think that physicians really struggle with that. I think it presents an opportunity for sponsors and CROs to really invest in a unified platform, that not only is consolidating trial information into one place, but it also allows for real time updates all in one interface, which is great. I think reducing the burden, of course, makes this process more efficient, but I think also what it does is that it increases the likelihood of clinical trials or pre-approval options to be considered at all, which ultimately is benefiting patients.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- How Sponsors Can Modernize Tools to Support Physicians
September 9th 2025
- Using AI Trial-Matching Tools to Accelerate Patient Access
September 8th 2025
- How AI Can Help Physicians Identify Eligible Trials Faster
September 5th 2025
- Why Many Health Tech Startups Miss the Mark in Clinical Trials
September 3rd 2025
- What Resilient Trial Design Means for Clinical Teams
September 2nd 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief Episode 7: Veeva and Merck Trial Efficiency, DCT Barriers, and Glucose Monitoring Strategies
2
Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19
3
Summit Therapeutics’ Bispecific Antibody Shows Positive Survival Trend in Non-Small Cell Lung Cancer
4
AstraZeneca’s Tagrisso Shows Landmark Overall Survival Benefit in Non-Small Cell Lung Cancer
5